pSivida, Alimera Sciences soar as Iluvien skips ahead to FDA review

Thu, 12/19/2013 - 1:58pm
Mass Device

pSivida's shares spike 35% on news that the company's Iluvien eye drug/device combination will skip ahead to final FDA review, bypassing the advisory panel process.

pSivida soars as copmany skips FDA avisory panel on review path for Iluvien

Massachusetts-based pSivida (NSDQ:PSDV) is making a comeback, with shares soaring on news that the company and its licensee Alimera Sciences (NSDQ:ALIM)  will get to skip past the advisory panel committee meeting and head straight to final FDA review for the Iluvien drug-device combination.

The regulatory win marks a major turnaround for the companies and the Iluvien product, which as been thrice denied by FDA regulators, most recently in October.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.